NCT07061769View on ClinicalTrials.gov

Helping Cancer Patients Manage Neuropathy Symptoms From Chemotherapy With a Low-Intensity, Low-Risk Cranial PEMF Device

NAEnrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 23, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

July 15, 2026

Conditions

Chemotherapy Induced Peripheral NeuropathyChemotherapy Induced Peripheral Neuropathy (CIPN)Chemotherapy Induced Pain NeuropathyChemotherapy Induced Neuropathic Pain

Interventions

DEVICE

SHIFT

SHIFT is a low intensity PEMF cranial device. It has been designated as a Non-Significant Risk device by the FDA.

Trial Locations (1)

92663

Hoag Spine Institute, Newport Beach

All Listed Sponsors

collaborator

Hoag Memorial Hospital Presbyterian

OTHER

lead

FluxWear, INC

INDUSTRY